Status:
UNKNOWN
Circulating Tumor Cells in mCRC for Liver Resection
Lead Sponsor:
The University of Hong Kong
Conditions:
Metastatic Colorectal Cancer
Circulating Tumor Cell
Eligibility:
All Genders
18+ years
Brief Summary
Resection of liver metastasis is potentially curative in patients with colorectal cancer bearing liver metastasis. However, early recurrence occurs in up to 30% in 3 months after liver resection. To o...
Detailed Description
This is a single-center prospective study to evaluate the predictive value of circulating tumor cells (CTC) in patients with metastatic colorectal cancer who are planned to have curative resection of ...
Eligibility Criteria
Inclusion
- Age\>=18 years
- Signed informed consent
- Histologically or cytologically confirmed colorectal adenocarcinoma
- Both primary tumor and liver metastases are amenable to curative resection.
Exclusion
- Presence of extrahepatic metastasis
- History of other malignancies in the last 5 years
- Patients unable to comply with the protocol
Key Trial Info
Start Date :
June 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2020
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT03295591
Start Date
June 1 2017
End Date
March 31 2020
Last Update
November 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Hong Kong
Hong Kong, Hong Kong